Skip to main content

Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy.

Publication ,  Journal Article
Harris, BS; Bishop, KC; Kuller, JA; Ford, AC; Muasher, LC; Cantrell, SE; Price, TM
Published in: Menopause
February 2020

OBJECTIVE: The aim of the study was to review the role of hormone therapy in menopausal patients with breast cancer and gynecologic malignancies. METHODS: We searched MEDLINE (via PubMed) using a combination of keywords and database-specific subject headings for the following concepts: menopause, hormone therapy, and cancer. Editorials, letters, case reports, and comments were excluded, as were non-English articles. Additional references were identified by hand-searching bibliographies of included articles. The searches yielded a total of 1,484 citations. All citations were imported into EndNote X9, where they were screened by the authors. RESULTS: In breast cancer survivors, systemic hormone therapy is not recommended, whereas local low-dose estrogen therapy may be considered after discussion with the patient's oncologist. Among endometrial cancer survivors, hormone therapy is considered safe in low-risk cancers but should be avoided in high-risk subtypes. For survivors of epithelial ovarian cancer and cervical cancer, hormone therapy can be considered, but should be avoided in women with estrogen-sensitive histologic subtypes. CONCLUSIONS: The risks of hormone therapy should be assessed on an individual basis, with consideration of age, type of hormone therapy, dose, duration of use, regimen, route, and prior exposure. Systemic hormone therapy is not recommended in breast cancer survivors, whereas vaginal low-dose estrogen appears safe. Hormone therapy may be used by endometrial, cervical, and ovarian cancer survivors with low-risk, non-estrogen-receptor-positive subtypes. Video Summary: http://links.lww.com/MENO/A516.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Menopause

DOI

EISSN

1530-0374

Publication Date

February 2020

Volume

27

Issue

2

Start / End Page

243 / 248

Location

United States

Related Subject Headings

  • Obstetrics & Reproductive Medicine
  • Middle Aged
  • Menopause
  • Humans
  • Genital Neoplasms, Female
  • Female
  • Estrogens
  • Estrogen Replacement Therapy
  • Contraindications, Drug
  • Cancer Survivors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Harris, B. S., Bishop, K. C., Kuller, J. A., Ford, A. C., Muasher, L. C., Cantrell, S. E., & Price, T. M. (2020). Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy. Menopause, 27(2), 243–248. https://doi.org/10.1097/GME.0000000000001447
Harris, Benjamin S., Katherine C. Bishop, Jeffrey A. Kuller, Anne C. Ford, Lisa C. Muasher, Sarah E. Cantrell, and Thomas M. Price. “Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy.Menopause 27, no. 2 (February 2020): 243–48. https://doi.org/10.1097/GME.0000000000001447.
Harris BS, Bishop KC, Kuller JA, Ford AC, Muasher LC, Cantrell SE, et al. Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy. Menopause. 2020 Feb;27(2):243–8.
Harris, Benjamin S., et al. “Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy.Menopause, vol. 27, no. 2, Feb. 2020, pp. 243–48. Pubmed, doi:10.1097/GME.0000000000001447.
Harris BS, Bishop KC, Kuller JA, Ford AC, Muasher LC, Cantrell SE, Price TM. Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy. Menopause. 2020 Feb;27(2):243–248.

Published In

Menopause

DOI

EISSN

1530-0374

Publication Date

February 2020

Volume

27

Issue

2

Start / End Page

243 / 248

Location

United States

Related Subject Headings

  • Obstetrics & Reproductive Medicine
  • Middle Aged
  • Menopause
  • Humans
  • Genital Neoplasms, Female
  • Female
  • Estrogens
  • Estrogen Replacement Therapy
  • Contraindications, Drug
  • Cancer Survivors